RxDoctor Payments Data

Kenneth Kepler, MD

Internal Medicine · Kihei, HINPI 1649360033

Payments from drug & device makers

$912in general payments, 2019–2025

Across 43 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nxstage Medical, Inc.$196
  • Pfizer$172
  • AstraZeneca$160
  • Bayer$126
  • AbbVie$63
  • Amgen$43
  • plus $151 from 6 others

What the payments were for

  • Food & beverage$912100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Nxstage Medical, Inc.4$196
Pfizer11$172
AstraZeneca(2 entities)12$160
Bayer1$126
AbbVie3$63
Amgen(2 entities)3$43
Merck3$37
GSK2$35
Sanofi-aventis U.S. LLC1$24
Gilead1$24
Melinta Therapeutics, LLC1$17
Teva Pharmaceuticals USA, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$912 in reported general payments places this provider in the 70th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$96,045
Medicare patients
310
Services billed
967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$140,708
EliquisApixaban62$79,653
RybelsusSemaglutide35$68,570
OzempicSemaglutide31$52,428
XareltoRivaroxaban30$47,880
Breo ElliptaFluticasone/Vilanterol56$27,959
MounjaroTirzepatide20$22,940
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$22,578
ProliaDenosumab11$19,071
Atorvastatin Calcium611$13,415
SymbicortBudesonide/Formoterol Fumarate14$7,840
Rosuvastatin Calcium130$6,004
Montelukast Sodium151$4,478
Novolog FlexpenInsulin Aspart17$4,266
Telmisartan94$3,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$172$79,65362 claims
GSKBreo Ellipta, Trelegy Ellipta$35$50,53674 claims
AmgenProlia$43$19,07111 claims
AstraZenecaSymbicort$160$7,84014 claims
AbbVieSynthroid$63$1,40220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Kihei

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →